BridgeBio Oncology Therapeutics, Inc.

Clinical-stage biopharma creating small molecule drugs for RAS-dependent cancers.

BBOT | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 256 E. GRAND AVENUE, SUITE 104, 94080 SOUTH SAN FRANCISCO
Website:: https://bbotx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical-stage biopharmaceutical company advancing a pipeline of novel small molecule therapeutics for precision oncology. The company leverages an expert understanding of RAS signaling biology to inform rational drug design, with a focus on treating RAS-dependent cancers. Its approach aims to maximize target inhibition by developing therapies that can inhibit a broad spectrum of KRAS mutants in both their active (ON) and inactive (OFF) states, as well as target RAS-driven PI3K activation. The company's mission is to translate this scientific knowledge into transformative medicines for patients with cancers that have clear genetic drivers.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all BridgeBio Oncology Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BridgeBio Oncology Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for BridgeBio Oncology Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
ANTEROGEN CO., LTD. Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.	South Korea	065660
Antibiotice S.A. Develops and manufactures generic medicines and APIs, specializing in anti-infectives.	Romania	ATB
Apellis Pharmaceuticals, Inc. Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.	United States of America	APLS
Apimeds Pharmaceuticals US, Inc. Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.	United States of America	APUS
Apogee Therapeutics, Inc. Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.	United States of America	APGE
Apollomics Inc. A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.	United States of America	APLM
Apontis Pharma AG German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.	Germany	APPH
APPLIED DNA SCIENCES INC Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.	United States of America	APDN
Applied Therapeutics, Inc. Develops treatments for rare metabolic and central nervous system (CNS) disorders.	United States of America	APLT
Aprea Therapeutics, Inc. Developing precision cancer therapies targeting DNA Damage Response for solid tumors.	United States of America	APRE